Skip to content
OpenCapital
Get started

Amgen AMGN BLINCYTO — Total revenues

Other product segments

Repatha
$3.02B—
Other products
$1.53B+3.6%
Prolia
$727M-33.8%
EVENITY
$562M+27.1%
TEPEZZA
$490M+28.6%
Otezla
$431M-1.4%
Nplate
$412M+31.6%
XGEVA
$411M-27.4%
TEZSPIRE
$343M+20.4%
KYPROLIS
$330M+1.9%
ENBREL
$320M-37.3%
Aranesp
$311M-8.5%
Vectibix
$287M+7.5%
UPLIZNA
$262M+188%
IMDELLTRA/IMDYLLTRA
$258M+219%
KRYSTEXXA
$255M+8.1%

Similar metrics at other companies

Schrodinger logo
SDGROncology, Neurology, and Immunology Product — Total revenues
$700K+16.7%
Bristol-Myers Squibb logo
BMYBreyanzi — Total Revenues
$484M+40.7%
Veracyte logo
VCYTBiopharmaceutical revenue — Total Revenue
$301K-86.9%
Gilead Sciences logo
GILDTotal Oncology — Total revenues
$810M+7.0%
Bristol-Myers Squibb logo
BMYReblozyl — Total Revenues
$735M+29.4%
BioMarin Pharmaceuticals logo
BMRNBRINEURA — Total revenues
$47.1M+16.7%

Other financials

Income statement

See full
Revenue$8.6B+5.8%
Gross profit$5.9B+13.4%
Operating income$2.7B+126%
Net income$1.8B+5.1%
EPS (diluted)$3.34+4.4%

Balance sheet

See full
Cash & equivalents$559.0M+10.0%
Total debt$57.3B-0.1%
Total equity$9.2B+48.1%
Total assets$92.5B+3.5%

Cash flow

See full
Operating cash flow$2.2B+57.4%
CapEx$712.0M+73.2%
Free cash flow$1.5B+50.7%

Valuation

See full
Market cap$212.16B+30.0%
Enterprise value$268.92B+22.9%
P/E27.2×+2.5×
P/S5.7×+1.0×

Profitability

See full
Gross margin68.3%+5.3pp
Operating margin28.4%+6.6pp
Net margin21%+3.6pp
FCF margin23.1%-8.9pp

Returns & leverage

See full
Return on equity101.3%-4.4pp
Debt / equity6.2×-3.0×
Current ratio1.3×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amgen's blincyto — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amgen's BLINCYTO — total revenues?
Amgen (AMGN) reported BLINCYTO — total revenues of $415M in Q1 2026.
How has Amgen's BLINCYTO — total revenues changed year-over-year?
Amgen's BLINCYTO — total revenues increased by 12.2% year-over-year, from $370M to $415M.
What is the long-term trend for Amgen's BLINCYTO — total revenues?
Over 4 years (2021 to 2025), Amgen's BLINCYTO — total revenues has grown at a 34.8% compound annual growth rate (CAGR), from $472M to $1.56B.
What does BLINCYTO — total revenues mean?
This metric represents the total gross sales generated from the specific biopharmaceutical product line within the oncology therapeutic portfolio. It reflects the market adoption, pricing power, and clinical utilization of this specific therapeutic agent for treating hematologic malignancies. Tracking this revenue stream provides insight into the commercial success and growth trajectory of the company's specialized cancer treatment offerings.